The Setup In 30 Seconds

Cardiol Therapeutics (NASDAQ: CRDL) develops drugs that target inflammation in the heart. Inflammation is the body's alarm system. Useful in short bursts. When it persists in the heart, it produces pain, swelling, and lasting damage.

Most heart drugs treat the consequences of inflammation — high blood pressure, weak pumping, scarring. Cardiol targets the alarm system itself.

The lead drug is CardiolRx, taken by mouth as a liquid. The company is also developing CRD-38, a subcutaneous (under-the-skin) formulation. Both are protected by U.S. patents in cardiac use through late 2040. Cardiol is based in Canada and is dual-listed on Nasdaq and the Toronto Stock Exchange under the same ticker, CRDL.

The pericardium is the thin sac that wraps around your heart. When it gets inflamed, it produces sharp chest pain, shortness of breath, and severe fatigue. For some patients, it comes back. And back. And back. That is recurrent pericarditis.

In the U.S., about 40,000 people are treated for it each year, and around 14,000 have repeat flare-ups.

Treatment starts with basic anti-inflammatory pills. When those fail, doctors escalate to steroids, which carry significant long-term side effects. Beyond steroids, the only branded option today is a weekly subcutaneous injection.

CardiolRx is being developed to fill the gap that exists today: an oral therapy positioned earlier in the treatment pathway, before patients exhaust steroids and move to chronic injectables.

Most clinical-stage biotech stories require investors to imagine a future market. CRDL does not. The market exists. It is measurable. And it is growing fast.

Kiniksa Pharmaceuticals (Nasdaq: KNSA) sells Arcalyst for recurrent pericarditis. The reported numbers tell the story:

• 2026 net product revenue guided to $930–$945 million.

And here is the part that matters most for CRDL: at year-end 2025, only ~18% of eligible patients were on therapy. Roughly 82% of the addressable population is still untreated by the branded option.

Cardiol's positioning is direct. The company has stated CardiolRx is being developed as "a non-immunosuppressive oral, more accessible therapy earlier in the treatment pathway".

Translation: the disease pays. Reimbursement is established. The branded category is growing at double-digit rates. And the dominant therapy is a chronic weekly injection — leaving a clear lane for an oral option positioned earlier in care.

In late 2025, Cardiol Therapeutics (NASDAQ: CRDL) reported topline results from ARCHER, a 109-patient mid-stage trial of CardiolRx in acute myocarditis (sudden inflammation of the heart muscle). The trial was randomized, double-blind, and placebo-controlled — the gold standard.

The headline result: a 9.2-gram reduction in left ventricular mass versus placebo, statistically significant at p=0.0117. When inflammation swells the heart, it pumps less efficiently. A measured shrinkage back toward normal is direct evidence that the drug is working on cardiac structure — not just symptoms.

The data were peer-reviewed and published in ESC Heart Failure — a journal of the European Society of Cardiology — in February 2026. Peer review means independent specialists examined the dataset and accepted it for publication. That is a meaningful credibility marker.

Why this matters for the MAVERIC thesis:

Most Phase 2 to Phase 3 transitions ask investors to bet on biology that has been suggested but not yet demonstrated in humans. ARCHER moved CRDL out of that category.

MAVERIC is the Phase 3 trial — the pivotal study designed to support a future FDA filing.

Key facts:

• Trial design was reviewed and aligned with the FDA at an end-of-Phase 2 meeting in April 2025 — meaning the agency agreed in advance on what would constitute a successful trial.

• Enrollment passed 50% in January 2026 and reached 75% by late April 2026. Execution has tracked or exceeded the company's stated timelines.

The trial's primary question is straightforward: do patients on CardiolRx experience fewer pericarditis recurrences than patients on placebo over six months? A successful primary endpoint result is what Cardiol Therapeutics (NASDAQ: CRDL) needs to support a future New Drug Application.

CRD-38 is being developed as a subcutaneous formulation for inflammatory heart disease, including heart failure. The company is preparing the regulatory paperwork (an Investigational New Drug, or IND, application) to begin Phase 1 human testing.

Cardiol has also reported it is "advancing discussions and negotiations with prospective strategic partners to provide global market access and maximize the commercial potential of the Company's drug candidates".

Cardiol Therapeutics (NASDAQ: CRDL) has reported the following on its capital position:

Two firms have published recent ratings on CRDL. Both are Buy:

• H.C. Wainwright: Buy, $9.00 price target, reiterated February 10, 2026. The firm's model assigns a 70% probability of success to the recurrent pericarditis program.

• Roth MKM: Buy, $10.00 price target. For broader consensus data, see TipRanks.

Context for retail investors:

Cardiol's SEC and Canadian filings — including its Annual Information Form filed March 31, 2026 — contain a complete description of risk factors. Investors are encouraged to review them on EDGAR and SEDAR+. Summary points:

Clinical outcomes are uncertain. The MAVERIC Phase 3 trial may or may not meet its primary endpoint. Phase 2 results do not guarantee Phase 3 results.

Pipeline concentration. CardiolRx in recurrent pericarditis is the lead and most advanced program; CRD-38 and the myocarditis program are at earlier stages.

Competition. Arcalyst (rilonacept), marketed by Kiniksa Pharmaceuticals, has been FDA-approved for recurrent pericarditis since 2021. Kiniksa is also developing KPL-387, with Phase 2 data expected in 2H 2026.

Capital requirements. CRDL has reported a cash runway into Q4 2027. Cardiol's public filings indicate that additional capital may be required to advance programs beyond current activities.

Regulatory review. FDA approval is not guaranteed even where a clinical trial meets its endpoint.

Stock characteristics. CRDL is a small-capitalization, dual-listed (Nasdaq and TSX) clinical-stage biotech. Trading volume is modest, and the share price has historically experienced significant volatility around news events.

Timing. Cardiol has stated MAVERIC enrollment is expected to complete in Q2 2026 with potential to extend into Q3 2026. Trial timelines in clinical development are subject to change.

The setup for Cardiol Therapeutics (NASDAQ: CRDL) is unusually well-defined for a clinical-stage biotech. The Phase 2 ARCHER results were peer-reviewed and published in a major cardiology journal. The Phase 3 MAVERIC trial is more than three-quarters enrolled at top-tier U.S. cardiovascular centers. The recurrent pericarditis indication is commercially established by an FDA-approved branded therapy generating roughly $900 million a year and growing at 60%+ — with most eligible patients still untreated.

On the other side: clinical trials carry outcome risk, the company faces an established competitor, and additional capital may be required to advance programs beyond current activities.

Investors should review the linked source materials, read CRDL's SEC and Canadian filings directly, and consult a qualified financial professional before making any investment decision.

• Cardiol Therapeutics company page: cardiolrx.com

• ARCHER Phase II trial registry: ClinicalTrials.gov NCT05180240

• ARCHER topline results (August 6, 2025): press release

• ARCHER full data presentation (December 1, 2025): press release

• ARCHER published in ESC Heart Failure (February 10, 2026): press release

• MAVERIC Phase III trial registry: ClinicalTrials.gov NCT06708299

• MAVERIC first patient enrolled (April 2025): press release

• MAVERIC 50% enrollment (January 13, 2026): press release

• MAVERIC 75% enrollment / site expansion (April 28, 2026): press release

• Cardiol Year-End 2025 Operations Update (April 1, 2026): press release

• Kiniksa Pharmaceuticals corporate update (January 12, 2026): press release

• Kiniksa Pharmaceuticals Q1 2026 results (April 28, 2026): press release

• Analyst ratings and price targets: Benzinga  |  TipRanks

• Real-time price and chart: Yahoo Finance

PAID ADVERTISEMENT — IMPORTANT DISCLOSURES

This communication is a paid advertisement and is not editorial content, independent research, or an unbiased analysis. Read this disclosure in full before reading the article it accompanies.

Compensation and source of payment. Elite Trade Club has received compensation of $15,000 in cash from Empire Market Ventures LLC, a third-party investor relations agency, for the production and hosted distribution of this communication regarding Cardiol Therapeutics Inc. (NASDAQ: CRDL; TSX: CRDL) for a period of two weeks beginning May 7, 2026. Elite Trade Club has not independently confirmed the ultimate source of the funds paid by Empire Market Ventures LLC and has not been informed by the agency of the identity of any party that retained or compensated the agency in connection with this communication. Readers should assume that the agency was retained by the featured company, an affiliate of the featured company, or a shareholder of the featured company, although Elite Trade Club cannot confirm this. This compensation creates a material conflict of interest. This communication should not be considered independent, unbiased, or the product of objective analysis.

Position disclosure. As of the date this communication is first published, Elite Trade Club holds no position, long or short, in CRDL or in any related security. Elite Trade Club and its officers, directors, employees, contractors, and persons under common control reserve the right to acquire, hold, or dispose of positions in CRDL or any related security at any time after publication, without further notice.

Selling-shareholder risk. The party or parties that funded this communication, and persons affiliated with that party, may currently hold shares in the featured company and may sell some or all of those shares during or after the distribution period of this communication, including into any buying interest this communication generates. Readers should assume that some of the buying interest generated by this communication may be met by selling from parties who funded or benefit from its distribution.

Not investment advice. Elite Trade Club is not a registered investment adviser, broker-dealer, or financial planner. Nothing in this communication constitutes investment, legal, tax, or other professional advice; a recommendation to buy, sell, or hold any security; or an offer or solicitation to purchase or sell any security. All content is for general informational purposes only.

Sources and verification. Information in this communication is drawn from the featured company's public disclosures and other publicly available sources, which are cited and linked within the article. Elite Trade Club has not independently verified the accuracy, completeness, or current applicability of any such information. Statements attributed to the featured company reflect the company's own statements and have not been independently confirmed by Elite Trade Club.

Speculative and high-risk securities. The securities discussed may be highly speculative and illiquid and involve a high degree of risk, including the risk of total loss of principal. Clinical-stage biotechnology companies in particular are subject to the risk of trial failure, regulatory rejection, additional capital requirements, and competitive displacement. Past performance is not indicative of future results.

Forward-looking statements. This communication contains forward-looking statements regarding clinical development, regulatory pathways, market opportunity, competitive dynamics, and other matters. Forward-looking statements involve known and unknown risks and uncertainties — including but not limited to clinical trial outcomes, regulatory review, competition, financing requirements, intellectual property, and general market conditions — that may cause actual results to differ materially from those projected or implied. Readers are referred to the featured company's filings with the U.S. Securities and Exchange Commission at sec.gov and Canadian securities regulators at sedarplus.ca for a complete description of risk factors.

No coordinated trading. Elite Trade Club is not engaged in any coordinated trading arrangement with the party that funded this communication or any of its affiliates.

Do your own due diligence. Before making any investment decision, conduct your own due diligence, review the featured company's public filings, and consult a licensed financial advisor regarding your individual circumstances.

Limitation of liability. Elite Trade Club shall not be liable for any direct, indirect, incidental, consequential, or other damages arising from your access to or reliance on this communication.

Distribution. This communication is being made available on a hosted web page operated by Elite Trade Club for a period of two weeks beginning May 7, 2026. By accessing this communication, the reader acknowledges having read and understood this disclosure.

Regulatory basis. This disclosure is made pursuant to Section 17(b) of the Securities Act of 1933 and the FTC Guides Concerning the Use of Endorsements and Testimonials in Advertising (16 CFR Part 255).